Karyopharm Therapeutics Inc.
KPTIDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
5
Next Catalyst
Aug 31, 2026
2dMarket Overview
Stock performance and key metrics
5 upcoming, 4 past
NDA Filing — Selinexor plus Ruxolitinib
For Myelofibrosis. Karyopharm plans to submit a supplemental NDA for selinexor plus ruxolitinib in myelofibrosis in August 2026 under the Accelerated Approval Pathway with a Priority Review request, based on compelling SVR35 data and preliminary overall survival data observed in topline results.
Source4 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How KPTI's past catalysts played out
Selinexor (combination therapy)
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Selinexor
Multiple Myeloma, Refractory
Selinexor 60 mg
Myelofibrosis
KPT-8602
Relapsed/Refractory Multiple Myeloma (RRMM)
Selinexor 100 mg
Non-Small Cell Lung Carcinoma (NSCLC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Selinexor (combination therapy) | Phase 3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | - | - |
Selinexor | Phase 3 | Multiple Myeloma, Refractory | - | - |
Selinexor 60 mg | Phase 2 | Myelofibrosis | - | - |
KPT-8602 | Phase 2 | Relapsed/Refractory Multiple Myeloma (RRMM) | - | - |
Selinexor 100 mg | Phase 2 | Non-Small Cell Lung Carcinoma (NSCLC) | - | - |
Myelofibrosis
4 drugs in this indication
endometrial cancer
2 drugs in this indication
TP53 wild-type advanced or recurrent endometrial cancer
1 drug in this indication
advanced or recurrent endometrial cancer with TP53 wild-type tumours
1 drug in this indication
Relapsed/Refractory Diffuse Large B-cell Lymphoma
1 drug in this indication
Non-Small Cell Lung Carcinoma (NSCLC)
1 drug in this indication
Relapsed/Refractory Multiple Myeloma (RRMM)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Karyopharm Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Karyopharm Therapeutics Inc.'s (KPTI) pipeline across Phase 3, Phase 2. Its lead program is Selinexor (combination therapy) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Karyopharm Therapeutics Inc.'s next FDA catalyst?→
Karyopharm Therapeutics Inc.'s (KPTI) next tracked catalyst is a NDA Filing expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KPTI biotech catalysts?→
Add KPTI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Karyopharm Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.